Insulin Resistance and Risk for Incident Heart Failure*

JACC: Heart Failure

Volumn 1, Issue 6, 2013, Pages 537-539

  McGuire, Darren K ^a   Gore, M Odette ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Heart failure; Insulin resistance; Obesity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN T;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EDITORIAL; GLUCOSE METABOLISM; HEART FAILURE; HEART PERFORMANCE; HIGH RISK PATIENT; HUMAN; INSULIN METABOLISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; FEMALE; MALE; PHYSIOLOGY;

FEMALE; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MALE;

EID: 84889071260     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.11.001     Document Type: Editorial

References (24)

1. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
2. Goyal A., Norton C.R., Thomas T.N., et al. Predictors of incident heart failure in a large insured population: a one million person-year follow-up study. Circ Heart Fail 2010, 3:698-705.
3. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). JAm Coll Cardiol 2001, 38:2101-2113.
4. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). JAm Coll Cardiol 2005, 46:e1-e82.
5. Vardeny O., Gupta D.K., Claggett B., et al. Insulin resistance and incident heart failure: the ARIC study (Atherosclerosis Risk in Communities). JAm Coll Cardiol HF 2013, 1:531-536.
6. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
7. Thrainsdottir I.S., Aspelund T., Thorgeirsson G., et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005, 28:612-616.
8. Mamas M.A., Deaton C., Rutter M.K., et al. Impaired glucose tolerance and insulin resistance in heart failure: Underrecognized and undertreated?. JCard Fail 2010, 16:761-768.
9. Matsushita K., Blecker S., Pazin-Filho A., et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes 2010, 59:2020-2026.
10. Saunders J., Mathewkutty S., Drazner M.H., McGuire D.K. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz 2008, 33:184-190.
11. Muhlestein J.B., Anderson J.L., Horne B.D., et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003, 146:351-358.
12. Brunner E.J., Shipley M.J., Witte D.R., Fuller J.H., Marmot M.G. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006, 29:26-31.
13. Agarwal S.K., Chambless L.E., Ballantyne C.M., et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail 2012, 5:422-429.
14. Nambi V., Liu X., Chambless L.E., et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk: the Atherosclerosis Risk in Communities Study. Clin Chem 2013 Sep 13, [E-pub ahead of print].
15. Dadu R.T., Dodge R., Nambi V., et al. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail 2013, 6:936-943.
16. Waheed S., Matsushita K., Sang Y., et al. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 2012, 60:207-216.
17. Zheng Y., Yu B., Alexander D., et al. Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study. Am J Epidemiol 2013, 178:534-542.
18. Rautaharju P.M., Zhang Z.M., Haisty W.K., et al. Electrocardiographic predictors of incident heart failure in men and women freefrom manifest cardiovascular disease (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2013, 112:843-849.
19. Roberts C.B., Couper D.J., Chang P.P., James S.A., Rosamond W.D., Heiss G. Influence of life-course socioeconomic position on incident heart failure in blacks and whites: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2010, 172:717-727.
20. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
21. Ingelsson E., Sundstrom J., Arnlov J., Zethelius B., Lind L. Insulin resistance and risk of congestive heart failure. JAMA 2005, 294:334-341.
22. Banerjee D., Biggs M.L., Mercer L., et al. Insulin resistance and risk of incident heart failure: Cardiovascular Health Study. Circ Heart Fail 2013, 6:364-370.
23. Kalogeropoulos A., Georgiopoulou V., Harris T.B., et al. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. JCard Fail 2009, 15:593-599.
24. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance invivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-E26.